The Ohio State University Launches NGS Cancer Panels Using Genomoncology’s GO Clinical Workbench

The Ohio State University Launches NGS Cancer Panels using GenomOncology’s GO Clinical Workbench in order to enable efficient clinical reporting of mutations detected from their next generation sequencing (NGS) results.

November 11, 2014

November 11, 2014 CLEVELAND, OH – GenomOncology announced today that the Ohio State University, College of Medicine, Department Of Pathology will use the company’s GO Clinical WorkbenchTM to enable clinical reporting of mutations detected from next generation sequencing (NGS). 

“Cancer is a complex disease, with tremendous diversity in pathology and genetics,” commented Weiqiang John Zhao, MD, PhD, FCAP, and Assistant Professor in the Clinical Pathology Branch, The Ohio State University. “The determination of genomic information from an individual’s tumor by NGS can be used to devise treatment approaches that are specific to that patient.” 

“NGS generates a significant amount of data and the process of developing clinically useful reports from this data is time consuming. The GO Clinical Workbench has helped us reduce the time to develop a clinically actionable report from half a day to less than an hour.” said Pamela Groen, Laboratory Manager. 

GenomOncology’s GO Clinical Workbench streamlines the use of Next Generation Sequencing (NGS) data and allows molecular pathology laboratories to produce an actionable clinical report using the molecular profile of an individual patient’s tumor. The platform is installed within the institutions firewall and is configured to each laboratory’s specific needs including integration with laboratory systems (LIMS, EMR, etc.), setting of quality control and annotation parameters and custom design of the clinical report. 

Today’s Molecular Pathology lab faces many challenges. Our goal is to enable the lab to produce a comprehensive clinical report that integrates therapy rules, supporting Levels of Evidence, active clinical trials, and complimentary testing modalities to best serve their Oncologists,” added Manuel Glynias, President and CEO of GenomOncology. “Generating this report in a highly efficient, scalable, and compliant manner is our primary focus.”



The clinical laboratories at The OSU Medical Center, The James Cancer Hospital, University Hospitals East and Martha Morehouse Medical Plaza continues to focus on implementation of new technology and auto-verification to provide high quality and timely results. The University Reference Laboratories, Inc. (URL) provides clinical laboratory services for outpatients of the OSUMC Health System and outreach clients. URL is a joint venture between the hospital and the pathology department, which ensures local availability of routine and esoteric laboratory testing. More information can be found at



GenomOncology is enabling precision medicine by translating next generation sequencing data into actionable information for clinicians and researchers. In collaboration with molecular pathologists and physicians, GenomOncology has developed the GO Clinical WorkbenchTM, a decision support tool with a step-by-step workflow that takes raw data from the sequencer and translates the specific molecular profile of each patient’s tumor genome into an actionable clinical report. GenomOncology’s research platform, GenomAnalyticsTM, allows scientists to analyze one or hundreds of genomes simultaneously to look for causal variants, reducing the time required to understand the genomic alterations that lead to new discoveries about the biology of cancer. More information can be found on the company’s website at